Abstract:There is a growing body of evidence that interventions like cognitive training or exercises prior to the manifestation of Alzheimer’s disease (AD) symptoms may decelerate cognitive decline. Nonetheless, evidence of prevention or a delay of dementia is still insufficient. Using OXYS rats as a suitable model of sporadic AD and Wistar rats as a control, we examined effects of cognitive training in the Morris water maze on neurogenesis in the dentate gyrus in presymptomatic (young rats) and symptomatic (adult rats… Show more
“…In these animals, all key signs of the disease develop spontaneously in the absence of mutations in genes App, Psen1, and Psen2 (Kolosova et al 2014;Stefanova et al 2015b;Telegina et al 2019; Kolosova et al 2022). As shown earlier, the rst neurodegenerative changes in OXYS rats occur at the age of 3 months against the background of an increased level of phosphotau (Stefanova et al 2015b;Rudnitskaya et al 2020); already during this period, their learning ability is altered (Burnyasheva et al 2020). In line with their hippocampus-dependent cognitive de cits, OXYS rats show a hippocampal synaptic loss (Stefanova et al 2015a), prominent alterations of synaptic functions (Beregovoy et al 2011;Rudnitskaya et al 2020), signi cant ultrastructural changes (Stefanova et al 2015b, a), and downregulated pre-and postsynaptic proteins (synapsin I and PSD-95, respectively), whose underexpression is considered an indicator event in AD (Stefanova et al 2016).…”
Glutamate and GABA are the most abundant neurotransmitters in the CNS and play a critical role in synaptic stability and plasticity. Glutamate and GABA homeostasis is important for healthy aging and for reducing the risk for various neurological diseases including Alzheimer’s disease (AD). Here we analyzed age-dependent alterations of expression of glutamate, GABA, and enzymes that synthesize them (glutaminase, glutamine synthetase, GABA-T, and GAD67), transporters (GLAST, GLT1, and GAT1), and relevant receptors (GluA1, NMDAR1, NMDA2B, and GABAAr1) in the whole hippocampus of Wistar rats and of senescence-accelerated OXYS rats. The latter are considered a suitable model of the most common (sporadic) type of AD. Our results suggest that in the hippocampus, there is a significant decline of glutamate and GABA signaling with aging (in Wistar rats), but in OXYS rats, there are no significant changes or compensatory enhancements in this system within the hippocampus during the development of neurodegenerative processes that are characteristic of AD.
“…In these animals, all key signs of the disease develop spontaneously in the absence of mutations in genes App, Psen1, and Psen2 (Kolosova et al 2014;Stefanova et al 2015b;Telegina et al 2019; Kolosova et al 2022). As shown earlier, the rst neurodegenerative changes in OXYS rats occur at the age of 3 months against the background of an increased level of phosphotau (Stefanova et al 2015b;Rudnitskaya et al 2020); already during this period, their learning ability is altered (Burnyasheva et al 2020). In line with their hippocampus-dependent cognitive de cits, OXYS rats show a hippocampal synaptic loss (Stefanova et al 2015a), prominent alterations of synaptic functions (Beregovoy et al 2011;Rudnitskaya et al 2020), signi cant ultrastructural changes (Stefanova et al 2015b, a), and downregulated pre-and postsynaptic proteins (synapsin I and PSD-95, respectively), whose underexpression is considered an indicator event in AD (Stefanova et al 2016).…”
Glutamate and GABA are the most abundant neurotransmitters in the CNS and play a critical role in synaptic stability and plasticity. Glutamate and GABA homeostasis is important for healthy aging and for reducing the risk for various neurological diseases including Alzheimer’s disease (AD). Here we analyzed age-dependent alterations of expression of glutamate, GABA, and enzymes that synthesize them (glutaminase, glutamine synthetase, GABA-T, and GAD67), transporters (GLAST, GLT1, and GAT1), and relevant receptors (GluA1, NMDAR1, NMDA2B, and GABAAr1) in the whole hippocampus of Wistar rats and of senescence-accelerated OXYS rats. The latter are considered a suitable model of the most common (sporadic) type of AD. Our results suggest that in the hippocampus, there is a significant decline of glutamate and GABA signaling with aging (in Wistar rats), but in OXYS rats, there are no significant changes or compensatory enhancements in this system within the hippocampus during the development of neurodegenerative processes that are characteristic of AD.
“…Recently, in a series of reports [22][23][24], we demonstrated the features of neurogenesis and neurotrophic and glial support of the brain in senescence-accelerated OXYS rats. OXYS rats were derived from the Wistar rat strain (normal healthy rats, control) and are characterized by accelerated senescence.…”
Section: Introductionmentioning
confidence: 98%
“…These neurodegenerative changes in the hippocampus of OXYS rats are accompanied by changes in the extracellular microenvironment of the neurogenic niche rather than by significant direct changes in the formation of new cells in the dentate gyrus (DG) [27]. Recently, we demonstrated that the density of amplifying neural progenitors (ANPs), which give rise to the neuronal cell lineage, is higher in OXYS rats than in Wistar rats during the completion of brain development, and, then, ANP density decreases [22]. Moreover, we showed the altered development of the hippocampus and prefrontal cortex in OXYS rats in an early postnatal period: a disturbance of astroglial support, a microglial deficiency, and a higher intensity of apoptosis during a period critical for the formation of a network among these brain structures [28].…”
Astrocytes and microglia are the first cells to react to neurodegeneration, e.g., in Alzheimer’s disease (AD); however, the data on changes in glial support during the most common (sporadic) type of the disease are sparse. Using senescence-accelerated OXYS rats, which simulate key characteristics of sporadic AD, and Wistar rats (parental normal strain, control), we investigated hippocampal neurogenesis and glial changes during AD-like pathology. Using immunohistochemistry, we showed that the early stage of the pathology is accompanied by a lower intensity of neurogenesis and decreased astrocyte density in the dentate gyrus. The progressive stage is concurrent with reactive astrogliosis and microglia activation, as confirmed by increased cell densities and by the acquisition of cell-specific gene expression profiles, according to transcriptome sequencing data. Besides, here, we continued to analyze the anti-AD effects of prolonged supplementation with mitochondria-targeted antioxidant SkQ1. The antioxidant did not affect neurogenesis, partly normalized the gene expression profile of astrocytes and microglia, and shifted the resting/activated microglia ratio toward a decrease in the activated-cell density. In summary, both astrocytes and microglia are more vulnerable to AD-associated neurodegeneration in the CA3 area than in other hippocampal areas; SkQ1 had an anti-inflammatory effect and is a promising modality for AD prevention and treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.